PDF
ePub
Citation
Print
Abstract
Purpose
Bacillus Calmette-Guerin (BCG) immunotherapy is the treatment of choice for adjuvant therapy of superficial bladder cancer. The outcomes of a 6 week course of BCG immunotherapy was compared with those of a modified 6+3 maintenance therapy.
Materials and Methods
Between January 2001 and June 2007, 123 patients with a superficial bladder cancer were treated with a transurethral resection of the bladder tumor (TURBT) and intravesical BCG. For the 93 patients, BCG was administered over a six week course. For the remaining 30 patients, BCG was administered for six weeks followed by three weekly instillations at 3, 6, 12, 18, 24 and 36 months. The recurrence rate, time to recurrence and progression rate were assessed and analyzed.
Results
In the six week therapy group, the overall recurrence rate, mean recurrence interval and median follow up was 31.2% (29/93), 15.9 months and 19.4 months, respectively. The recurrence rate according to stage and grade was 27.6% (8/29), 33.9% (21/62) and 0% (0/2) on Ta, T1 and carcinoma in situ (CIS), respectively, and 29.6% (21/71), 40% (8/20) in low grade and high grade, respectively. Five cases in the T1 high grade and 1 case in T1 low grade group progressed to T2. In maintenance therapy, the overall recurrence rate, mean recurrence interval and median follow up was 16.7% (5/30), 16.4 months and 24.8 months, respectively. The recurrence rate according to stage and grade was 14.3% (1/7), 14.3% (3/21) and 50% (1/2) on Ta, T1, CIS, respectively, and 15.0% (3/20), 12.5% (1/8) in low grade and high grade, respectively. One case in the CIS sub group progressed to T4a.
Figures and Tables
Fig. 1
Kaplan-Meier analysis of the accumulative recurrence between the 6 week therapy and modified 6+3 maintenance therapy groups.
Table 1
Patients' characteristics in the six week therapy and modified 6+3 maintenance therapy groups
Table 2
Recurrence rate according to stage and grade in the six week therapy and modified 6+3 maintenance therapy groups
References
1. Jones JS, Campbell SC. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Non-Muscle-Invasive bladder cancer (Ta, T1, and CIS). Campbell-Walsh urology. 2007. 9th ed. Philadelphia: Saunders;2447–2467.
2. Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro L Jr, Fiter L, Mosteiro JA, Navarro J, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990. 143:502–506.
3. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991. 325:1205–1209.
4. Lundholm C, Norlen BJ, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T, et al. A randomized prospective study comparing long-term intravesical instillation of mitomycin C and Bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1996. 156:372–376.
5. Kavoussi LR, Torrence RJ, Gillen DP, Hudson MA, Haaff EO, Dresner SM, et al. Results of 6 weekly intravesical Bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J Urol. 1988. 139:935–940.
6. Lamm DL, Sarosdy MF, Grossman ED. Maintenance vs. non-maintenance BCG immunotherapy of superficial bladder cancer: a Southwest Oncology Group study. J Urol. 1990. 143:Suppl. 341A. abstract 610.
7. Kim WJ, Chung JI, Hong JH, Kim CS, Jung SI, Yoon DK. Epidemiological study for urologic cancer in Korea (1998-2002). Korean J Urol. 2004. 45:1081–1088.
8. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficail bladder tumors. J Urol. 1976. 116:180–183.
9. Hudson MA, Ratliff TL, Gillen DP, Haaff EO, Dresner SM, Catalona WJ. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol. 1987. 138:295–298.
10. Park JW, Park CH, Kim CI. Superficial bladder carcinoma treated with Bacillus Calmette-Guerin: minimum 5-year follow up results. Korean J Urol. 2003. 44:573–578.
11. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000. 163:1124–1129.
12. Sylvester RJ, Van der Meijden AP, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002. 168:1964–1970.
13. Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF Jr, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical Bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol. 1987. 5:441–449.
XML Download